Cite
MLA Citation
Thomas E. Delea et al.. “Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.” Journal of medical economics, vol. 22, 2019, pp. 117–130. http://access.bl.uk/ark:/81055/vdc_100077270809.0x00001e